ArticleMovement disorders : official journal of the Movement Disorder Society2022
Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.
Article in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 35 citations in OpenAlex.
- Longitudinal Videofluorographic Dysphagia Measures in Progressive Supranuclear Palsy.Movement disorders clinical practice · 2026Article
- A Brainstem Radiomics Framework to Distinguish Progressive Supranuclear Palsy from Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.Brain sciences · 2026Article
- Magnetic resonance imaging volumetry in atypical parkinsonism: current evidence and neuroradiological perspectives.Frontiers in aging neuroscience · 2026Review
- Patterns of Longitudinal Regional Brain Atrophy in Patients With Different Progressive Supranuclear Palsy Clinical Variants.Neurology · 2025Article
- Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework.Journal of neurology · 2025Review
- Uncovering Image-Driven Subtypes with Distinct Pathology and Clinical Course in Autopsy-Confirmed Four Repeat Tauopathies.Annals of neurology · 2025Article
- Machine Learning Models of Voxel-Level [Annals of neurology · 2025Article
- Diagnostic utility of tectal plate measures in clinical variants of progressive supranuclear palsy.Journal of neurology · 2025Article
- In search of the optimal MRI marker for progressive supranuclear palsy: a large, single-center, retrospective study on the effect of phenotype, diagnostic certainty and disease duration.Journal of neurology · 2025Article
- Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Multimodality Brain Imaging Markers in Progressive Supranuclear Palsy Subtypes and Parkinson's Disease.Movement disorders clinical practice · 2025Article
- Magnetic Resonance Imaging in the Neuroimaging of Progressive Supranuclear Palsy-Parkinsonism Predominant: Limitations and Strengths in Clinical Evaluation.Diagnostics (Basel, Switzerland) · 2025Article
- Evaluation of disproportionately enlarged subarachnoid-space hydrocephalus in progressive supranuclear palsy.Brain communications · 2025Article
- Brainstem and cerebellar radiological findings in progressive supranuclear palsy.Brain communications · 2025Review
- Clinical Utility of Tectal Plate Measurements on Magnetic Resonance Imaging in Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants.Journal of neurology · 2024Article
- Direct comparison betweenNeuroImage · 2024Article
- Planimetric and Volumetric Brainstem MRI Markers in Progressive Supranuclear Palsy, Multiple System Atrophy, and Corticobasal Syndrome. A Systematic Review and Meta-Analysis.Neurology international · 2023Review
- Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome.Movement disorders : official journal of the Movement Disorder Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMagnetic resonance brainstem measurements are useful structural biomarkers in the Richardson's syndrome variant of progressive supranuclear palsy (PSP). However, it is unclear how these biomarkers differ across the phenotypic spectrum of PSP and how they relate to underlying pathology.
objectiveThe aim of this study was to compare brainstem imaging measures across clinical variants of PSP and determine sensitivity and specificity based on pathologically diagnosed cases.
methodsA total of 153 patients with PSP who represented eight clinical variants were recruited at Mayo Clinic (Rochester, MN, USA) and underwent structural magnetic resonance imaging (MRI). Midbrain and pons area and superior and middle cerebellar peduncle width measurements were performed, and midbrain/pons ratio and Magnetic Resonance Parkinsonism Index (MRPI) were calculated. Among the 43 patients who later died, PSP pathology was confirmed in 29, whereas 14 had other pathology.
resultsBrainstem measurements varied across PSP clinical variants and were most abnormal in PSP-Richardson's syndrome and frontal variants, followed by PSP-corticobasal, PSP-speech/language, and PSP-parkinsonism variants. All these variants showed abnormalities compared with controls. The PSP-gait freezing variant and patients with prominent corticospinal tract signs showed normal brainstem measures. Among cases with confirmed PSP pathology, the midbrain area, midbrain/pons ratio, and MRPI were all more abnormal compared to those with other pathologies, with best differentiation obtained with the MRPI (sensitivity = 83%; specificity = 85%).
conclusionsMRI brainstem measures show utility as diagnostic biomarkers across PSP clinical variants and have the potential to be useful in predicting underlying pathology. © 2021 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.